This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Jul;40(1):260-3.

doi: 10.1002/hep.20294.

The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?

Michael Trauner¹

Affiliations

Affiliation

¹ Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria.

PMID: 15239110
DOI: 10.1002/hep.20294

Comment

The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?

Michael Trauner. Hepatology. 2004 Jul.

. 2004 Jul;40(1):260-3.

doi: 10.1002/hep.20294.

Author

Michael Trauner¹

Affiliation

¹ Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria.

PMID: 15239110
DOI: 10.1002/hep.20294

No abstract available

PubMed Disclaimer

Comment on

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.
Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Liu Y, et al. J Clin Invest. 2003 Dec;112(11):1678-87. doi: 10.1172/JCI18945. Epub 2003 Nov 17. J Clin Invest. 2003. PMID: 14623915 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database